Home › Squamous Cell Carcinoma ng Ulo at Leeg › Oregon

Pag-aaral pangklinika para sa Squamous Cell Carcinoma ng Ulo at Leeg sa Oregon

19 pag-aaral para sa Squamous Cell Carcinoma ng Ulo at Leeg ang naghahanap ng mga kalahok sa mga site sa Oregon.

Mga Lungsod sa Oregon

Opisyal na teksto ng pag-aaral (English)

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

Providence Newberg Medical Center, Newberg
Providence Portland Medical Center, Portland
Providence Saint Vincent Medical Center, Portland

Nagre-recruitPhase 2

Edad 18 hanggang 79 · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT04671667

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

Saint Charles Health System, Bend
Clackamas Radiation Oncology Center, Clackamas
Providence Newberg Medical Center, Newberg
at 4 pa

Nagre-recruitPhase 2

Edad 18 pataas · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT05136196

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

Saint Alphonsus Cancer Care Center-Ontario, Ontario
Providence Willamette Falls Medical Center, Oregon City
Providence Portland Medical Center, Portland
at 1 pa

Nagre-recruitPhase 3

Edad 18 pataas · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT06589804

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

Oregon Health And Science University, Portland

Nagre-recruitPhase 3

Edad 18 pataas · Lahat ng kasarian · Na-update Nob 3, 2026 · NCT07276399

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

Oregon Health And Science University, Portland

Nagre-recruitPhase 3

Edad 60 pataas · Lahat ng kasarian · Na-update Nob 3, 2026 · NCT04892173

FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

Providence Portland Medical Center (Site #0113), Portland

Nagre-recruitPhase 2/3

Edad 18 pataas · Lahat ng kasarian · Na-update Okt 29, 2026 · NCT06788990

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

USA15-0, Portland

Nagre-recruitPhase 2

Edad 18 pataas · Lahat ng kasarian · Na-update Okt 29, 2026 · NCT06953089

A Study of MGC026 in Participants With Advanced Solid Tumors

Providence Cancer Institute, Portland

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Okt 28, 2026 · NCT06242470

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

Oregon Health and Science University, Portland

Nagre-recruitPhase 2

Edad 18 pataas · Lahat ng kasarian · Na-update Okt 26, 2026 · NCT06980038

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

OHSU Knight Cancer Institute, Portland

Nagre-recruitPhase 4

Edad 18 pataas · Lahat ng kasarian · Na-update Okt 13, 2026 · NCT07405086

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

Exelixis Clinical Site #51, Portland

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Okt 1, 2026 · NCT05176483

A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors

Site 02, Portland

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Set 30, 2026 · NCT07814248

A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors

ALX Center 6, Portland

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Set 30, 2026 · NCT07085091

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Research Site, Portland

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Set 29, 2026 · NCT05877599

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

Saint Alphonsus Cancer Care Center-Baker City, Baker City
Saint Charles Health System, Bend
Clackamas Radiation Oncology Center, Clackamas
at 8 pa

Nagre-recruitPhase 2

Edad 18 pataas · Lahat ng kasarian · Na-update Set 14, 2026 · NCT02734537

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

Clackamas Radiation Oncology Center, Clackamas
Providence Portland Medical Center, Portland
Providence Saint Vincent Medical Center, Portland

Nagre-recruitPhase 2/3

Edad 18 pataas · Lahat ng kasarian · Na-update Ago 17, 2026 · NCT04333537

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

Providence Cancer Center Oncology and Hematology Care- Eastside, Portland

Nagre-recruitPhase 1/2

Edad 18 pataas · Lahat ng kasarian · Na-update Ago 17, 2026 · NCT04895709

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Providence Cancer Institute Franz Clinic, Portland

Nagre-recruitPhase 1/2

Edad 18 pataas · Lahat ng kasarian · Na-update Hul 7, 2026 · NCT05768139

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Providence Cancer Institute Franz Clinic, Portland
Providence Oncology and Hematology Care Clinic - Westside, Portland
Providence St. Vincent Medical Center- Investigational Drug Services, Portland
at 1 pa

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Hul 6, 2026 · NCT04389632

Mula sa ClinicalTrials.gov, na-kuha noong Nob 15, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.